Lipid metabolic reprogramming mediated by circulating Nrg4 alleviates metabolic dysfunction-associated steatotic liver disease
1. In patients with obesity who had previously undergone a sleeve gastrectomy and are in the early phases of recovery, ...
Tag: hepatology
2 Minute Medicine Rewind April 8, 2024
Efficacy and safety of sitagliptin with basal-plus insulin regimen versus insulin alone in non-critically ill hospitalized patients with type 2 ...
Low vitamin D levels accelerates muscle mass loss in patients with chronic liver disease
1. In a cohort of patients with chronic liver disease, low vitamin D levels were significantly and independently associated with ...
2 Minute Medicine Rewind April 1, 2024
Sarcopenia and Sarcopenic Obesity and Mortality Among Older People 1. In this secondary analysis of the Rotterdam study, older adults ...
Magnetically guided capsule endoscope with detachable string promising for diagnosing esophagogastric varices
1. In a large prospective multicentre diagnostic accuracy study, magnetically guided capsule endoscopy with a detachable string (ds-MCE) demonstrated high ...
2 Minute Medicine Rewind March 11, 2024
Early vs Late Fixation of Extremity Fractures Among Adults With Traumatic Brain Injury 1. In a cohort of patients with ...
Metabolic-dysfunction associated steatotic liver disease likely increases risk of dementia
1. Vascular dementia may be increased by metabolic dysfunction associated steatotic liver disease (MASLD), liver fibrosis, and cirrhosis. Evidence Rating ...
Dietary niacin supplementation may reduce mortality risk in patients with non-alcoholic fatty liver disease
1. Among participants with non-alcoholic fatty liver disease, greater consumption of dietary niacin was associated with a reduction in the ...
Non-alcoholic fatty liver disease increases cardiovascular and mortality risk in patients with diabetes
1. The risk of cardiovascular disease (CVD) and all-cause death for individuals with type 2 diabetes mellitus (T2DM) is increased ...
Resmetirom improves liver fibrosis in nonalcoholic steatohepatitis
1. In this randomized controlled trial, among patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis, resmetirom was superior to placebo ...
